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The human microbiome and juvenile
idiopathic arthritis
Anouk Verwoerd1, Nienke M. Ter Haar1, Sytze de Roock1, Sebastiaan J. Vastert1,2† and Debby Bogaert3*†
Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The pathogenesis of JIA is
thought to be the result of a combination of host genetic and environmental triggers. However, the precise factors
that determine one’s susceptibility to JIA remain to be unravelled. The microbiome has received increasing attention as
a potential contributing factor to the development of a wide array of immune-mediated diseases, including
inflammatory bowel disease, type 1 diabetes and rheumatoid arthritis. Also in JIA, there is accumulating evidence that
the composition of the microbiome is different from healthy individuals. A growing body of evidence indeed suggests
that, among others, the microbiome may influence the development of the immune system, the integrity of the
intestinal mucosal barrier, and the differentiation of T cell subsets. In turn, this might lead to dysregulation of the
immune system, thereby possibly playing a role in the development of JIA. The potential to manipulate the
microbiome, for example by faecal microbial transplantation, might then offer perspectives for future therapeutic
interventions. Before we can think of such interventions, we need to first obtain a deeper understanding of the cause
and effect relationship between JIA and the microbiome. In this review, we discuss the existing evidence for the
involvement of the microbiome in JIA pathogenesis and explore the potential mechanisms through which the
microbiome may influence the development of autoimmunity in general and JIA specifically.
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Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood, with a prevalence of
16−150 cases per 100,000 children [1]. By definition, it is
characterised by arthritis of unknown origin persisting for
more than 6 weeks, and starting before the age of 16 years
[1, 2]. Several different types of JIA can be defined, among
which are oligoarticular, polyarticular and systemic JIA.
This review will focus on oligoarticular and polyarticular
JIA, for which an underlying autoimmune pathogenesis is
assumed [1]. Despite recent advancements in our under-
standing of the inflammatory process that characterises
JIA and the development of new treatment strategies, the
precise factors that determine one’s susceptibility to JIA
remain to be identified.
The microbiota has recently received increasing atten-
tion as a potential contributing factor to the development
of a wide variety of health problems, including immune-
mediated diseases [3]. The microbiota is a collective term
for the trillions of microorganisms that inhabit our epithe-
lial surfaces, including the gut, respiratory tract and skin.
The collection of genes encompassed by the micro-
biota is referred to as the “microbiome”. Recent ad-
vances in high-throughput sequencing have enabled
the detailed study of the composition of the micro-
biome and host-microbe interactions [4]. These stud-
ies have revealed that the complex interplay between
the immune system and the microbiota is essential for a
healthy development of the immune system and for pro-
tecting the host against colonization, overgrowth and in-
vasion of pathogens [3]. The disruption of this mutualistic
relationship can lead to an imbalance in the composition
of the microbiota, or “dysbiosis”, which is thought to play
a role in the development of numerous immune-mediated
diseases, such as inflammatory bowel disease, type 1 dia-
betes, and rheumatoid arthritis (RA) [5–7].
Factors that have been associated with dysbiosis so far
are diet and lifestyle, pathogens and drug use – especially
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the use of antibiotics [8–10]. Indeed, preliminary studies
have demonstrated that the composition of the micro-
biome may be altered in JIA [11]. Furthermore, recent
publications have suggested that early life antibiotic use is
associated with a higher risk of development of JIA later
in life [12, 13]. In this review, we explore the poten-
tial role of the microbiome in the pathogenesis of
JIA, and provide an overview of the current evidence
supporting this hypothesis.
Disease mechanisms in JIA
The pathogenesis of JIA is currently thought to be the
result of a combination of factors: in a genetically sus-
ceptible individual, exposure to one or more environ-
mental triggers may lead to local tissue damage and/or
the release of self-antigens, finally resulting in chronic syn-
ovial inflammation [1]. Preliminary evidence for a genetic
component in the underlying aetiology of JIA initially
came from twin and family studies. These studies have
demonstrated a higher prevalence of JIA in twin and non-
twin siblings of children with JIA, as well as similarities in
disease course. Concordance rates between monozygotic
twins were found to be 20–40 % [14, 15]. However, one
must note that other non-genetic factors, including the
composition of the microbiome, are highly similar in twins
as well [16], making it difficult to differentiate between
these factors. Recently, a large genome-wide association
study with more than 2800 JIA cases and more than
13,000 healthy controls, however, indicated that only 18 %
of JIA pathogenesis could be attributed to genetic factors
[17]. The remaining part should therefore be explained by
non-hereditary, possibly environmental influences these
children commonly experience.
With respect to genetic susceptibility, multiple specific
susceptibility genes have been identified, which can be
broadly subdivided in HLA and non-HLA genes and dif-
fer between subtypes of JIA. For example, oligoarticular
JIA is associated with HLA-A2, -DR5 and -DR8, whereas
rheumatoid factor (RF-) negative polyarticular JIA is as-
sociated with the DRB1*08 and DBP1*03 haplotypes.
RF-positive polyarticular JIA, on the contrary, is associ-
ated with DRB1*04, DQA1*03 and DQB1*03 [18]. The
strong association of HLA-genes with JIA underscores
the importance of T cells in pathogenesis of disease.
Non-HLA genes that are linked to JIA mostly relate to
the immune system and its cytokines. An example is
IL2RA, encoding the alpha chain of the interleukin (IL)-
2 receptor, which is associated with persistent oligoarti-
cular JIA [2]. Other examples are macrophage inhibiting
factor (MIF) and tumour necrosis factor (TNF), which
are both associated with JIA in general [2]. One can im-
agine that these polymorphisms also indirectly influence
the composition of the microbiome by having an effect
on the immune response in general.
Although these genetic factors are important in explain-
ing part of the complex pathogenesis of JIA, as said, con-
comitant environmental triggers may too likely play an
important role. Infectious agents are considered as one of
the potential environmental triggers of JIA pathogenesis
[18, 19], possibly due to molecular mimicry of bacterial
peptides with self-antigens. Both viruses (e.g. Parvovirus
B19 and Epstein-Barr virus) and bacteria (e.g. Enterobac-
ter spp., Chlamydophila pneumoniae and Streptococcus
spp.) were studied as potential trigger of disease, but re-
sults remain inconclusive due to the unavailability of con-
trolled prospective studies that are needed to identify
drivers of disease in a time-dependent fashion.
On a cellular level, however, immune responses to-
wards self-antigens are hypothesised to be a central
event in the development of JIA. This is supported by
the observation of clustering of memory T cells around
antigen-presenting cells in the synovium of JIA patients,
which are predominantly IFNγ+ and of the Th1 pheno-
type [1, 20]. Also T helper 17 (Th17) cells are, among
others, found in the joints of children with JIA [21].
Interestingly, it was found that shifting from a Th17
phenotype to a Th17/Th1 or Th1 phenotype can occur
in the synovial fluid of oligoarticular JIA patients during
the disease course, underlining the involvement of differ-
ent sets of effector T cells in the chronic synovial inflam-
mation central to JIA [22]. In addition, regulatory T cells
(Tregs) have been implicated in JIA and other auto-
immune diseases because of their role in regulating and
dampening aberrant immune responses [23]. In JIA, in-
creased numbers of Tregs are found at the site of in-
flammation, which raises the question whether they
retain their suppressive capacity at the site of inflamma-
tion. Indeed, effector T cells in the synovial fluid have
shown to be resistant to suppression by Tregs [24].
Altogether, these observations contribute to a disease
concept of JIA in which the balance between regulatory
(T) cells and effector (T) cells is disturbed, resulting in
chronic joint inflammation.
In addition to the adaptive immune system, it is now in-
creasingly understood that also the innate immune system
plays a role in the disease mechanisms of JIA [2, 25]. This
is for example illustrated by the role of granulocyte-
macrophage colony stimulating factor (GM-CSF), a potent
inflammatory mediator responsible for the induction of
innate immune cells, such as neutrophils and monocytes,
in autoimmune disease. Interestingly, a recent study pos-
tulated that Th17 plasticity is a key driver of GM-CSF
production in JIA tying these two observations together in
one possible mechanistic route [26].
The microbiome and the immune system
Encoding 9.8 million non-redundant genes and 100-fold
more proteins than the human genome [27, 28], the gut
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microbiome provides an enormous source of antigenic
variation. This variation is indispensable for a healthy
development of the immune system, and helps the im-
mune system recognise the normal microenvironment.
The reciprocal interaction between the host and micro-
biota offers mutual benefits: while the host provides the
microbiota with a niche and essential nutrients, the
microbiota regulates a variety of physiological processes
essential to the host [3]. Among others, the microbiota-
contributes to the production of vitamins, and prevents
invasion of pathogens by competing for nutrients [3,
29]. Furthermore, the host’s immune response to the
microbiotamay also impact and shape the microbial
ecosystem in the long term [3, 30]. On the other hand,
the microbiota might potentially play a role in the gen-
eration of autoimmunity by triggering the immune sys-
tem in an aberrant way or inducing cross-reactivity to
self-antigens [8]. The balance between tolerance and
activation seems delicate again: the immune system
must be able to respond to any potentially harmful
non-self antigen, while it should not eliminate its indis-
pensable commensals [8].
The microbiome influences development of the immune
system
The microbiome shapes the host immune system in a
variety of ways. First, it affects development of the intes-
tinal mucosal barrier itself [3, 31]. Underdevelopment of
this barrier, possibly through an imbalance in the micro-
bial community and release of inflammatory triggers like
LPS, might lead to increased gut permeability, which in
turn might result in the spread of bacterial components
and (systemic) inflammation [31]. Secondly, studies using
germ-free mice have demonstrated that the microbiome is
essential for the normal generation and maturation of gut-
associated lymphoid tissue (GALT) [32, 33]. Since GALT
are structures in which antigenic presentation takes place,
normal development of GALT is important for a healthy
development of the immune system.
In addition to GALT, the microbiome was found to
have a direct influence on the development of T cells,
among others Th1 and Th17 cells [34, 35]. Th17 cells
preferentially develop in the intestinal mucosa [36].
Numbers of Th17 cells were observed to be significantly
reduced in antibiotic-treated and germ-free mice, impli-
cating a role for the microbiome in Th17 immune devel-
opment [34]. Restoring the microbiome of germ-free mice
with stools of healthy mice results in normalization of in-
testinal Th17 cell numbers. Although the precise mechan-
ism by which the microbiome induces Th17 development
remains to be elucidated, it was found in one study that
murine segmented filamentous bacteria (SFB), which are
non-culturable Clostridium-species, seem to induce Th17
cell development in the lamina propria of the small
intestine [35]. Importantly, Th17 cells can transform into
Th1 cells under the influence of IL-22 or IL-23 signalling
[37], as was described above for JIA [22].
In a similar fashion, the microbiome composition ap-
pears to influence the development of Tregs. Levels of
Tregs were significantly reduced in germ-free mice [38].
Studies have shown that specific populations of com-
mensal bacteria may induce the development of Tregs in
mice, including again Clostridium spp., especially
Clostridia clusters IV, XIVa and XVIII [38]. This was
found to occur through the production of short-chain
fatty acids (SCFAs), especially butyrate, which inhibit his-
tone deacetylases. As histone deacetylases normally result
in Treg induction, inhibition by butyrate would decrease
Treg numbers. [39]. Also colonization of B. fragilis, a hu-
man commensal, was found to induce Tregs in mice [3].
As outlined above, Th1 cells, Th17 cells and Tregs are
generally assumed to play a central role in development
of autoimmunity [40]. Imbalance between these cell sub-
sets resulting from the possible induction of Th1/Th17
cells over Tregs might trigger or at least sustain auto-
immune responses. A recent review by Rogier et al.
poses that the imbalance might be triggered by the
microbiome community members through activations of
Toll-like receptors (TLRs) [41]. TLR activation on
antigen-presenting cells (APCs) enhances the antigenic
signal to T cells by inducing the upregulation of MHCII,
co-stimulatory molecules and the release of cytokines,
and thereby shapes T helper cell subsets [41].
The microbiome as mediator of autoimmunity?
As described above, accumulating evidence suggests that
the microbiome influences the development and func-
tion of the immune system. Furthermore, the cellular
mechanisms behind these interactions are beginning to
be unfolded. However, the question remains how
microbes can act as mediators/inducers of autoimmune
responses and contribute to autoimmune disease. A num-
ber of theories have been developed, of which molecular
mimicry is the most well-known.
Molecular mimicry refers to the phenomenon in which
a foreign antigen has structural similarities with self-
antigens, typically leading to the formation of cross-
reactive antibodies and T cells [8, 42]. Rheumatic fever is
a well-known example in which severe systemic disease
is caused by the generation of cross-reactive antibodies
against group A streptococcus [43]. In addition, accumu-
lating evidence suggests that commensals can induce
cross-reactive lymphocytes [44, 45]. However, under
physiological conditions, cross-reactive T cells should be
more of the regulatory phenotype [8]. This therefore
raises the hypothesis that as a result of immune-
modulatory effects of the microbial community as de-
scribed above, skewing of this cross-reactive immune
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response towards a more pathogenic T cell subset might
explain the autoimmune phenomena. In addition, skew-
ing of T cell responses may also occur in cases of muco-
sal barrier disruption. Studies have shown that a break
in T cell tolerance may occur as a result of disruption of
the intestinal mucosal barrier following invasion of path-
ogens [8, 46]. Since the microbial community in the in-
testine is highly involved in mucosal integrity and
barrier function, both processes of immune-skewing and
breakage of T cell tolerance might occur in parallel as a
consequence of a physiological response, however, even-
tually leading to autoimmune inflammation.
Another possible mechanisms by which the microbiome
may contribute to the generation of autoimmunity is by-
stander activation, which might occur with or without epi-
tope spreading [47, 48]. Bystander activation refers to an
indirect activation of autoreactive cells caused by the re-
lease of pro-inflammatory cytokines during inflammation
or tissue damage, for example as a result of a dysbiotic en-
vironment. Epitope spreading occurs when an immune re-
sponse directed against a specific (microbial) antigen
includes different portions of the same or similar proteins
[49, 50]. This activates a broader set of T cells, which in
physiological circumstances helps to support the efficient
elimination of the pathogen. However, under unbeneficial
conditions, this might also lead to the indirect activation
of autoreactive T cells thereby contributing to the gener-
ation of autoimmunity [8, 47].
Lastly, some microbes might alter host proteins, thereby
creating new antigens that are recognized by the adaptive
immune system as non-self [47]. An example is Porphyro-
monas gingivalis, which is able to citrullinate host pro-
teins, thereby inducing the characteristic antibodies to
citrullinated protein antigens (ACPAs) in RA [51].
Evidence for involvement of the microbiome in JIA
Considering the delicate interaction between the im-
mune system and the microbiome, and the recent evi-
dence suggesting that the human microbiome may play
a role in the generation of autoimmunity in general, one
can imagine that the interaction of the immune system
and the microbiome may contribute to the development
of JIA. Multiple studies have addressed the potential role
of the microbiome in JIA, which are summarised in
Table 1. In addition to these studies, which predomin-
antly included patients with oligo- and polyarticular JIA,
the role of the microbiome in the pathogenesis of
enthesitis-related arthritis (ERA) – another distinct sub-
type of JIA – was also studied and already reviewed
comprehensively by Gill et al. (section on juvenile spon-
dyloarthritis) [52, 53]. For example, Malin et al. studied
bacterial enzyme activities in faeces of JIA patients and
compared this to healthy controls [54]. They found in-
creased bacterial urease activity in faecal samples of JIA
patients, and reasoned that this might be a result of al-
terations in the anaerobic bacterial flora [54]. They also
showed that by the administration of a human Lactoba-
cillus strain, faecal urease activity could be again dimin-
ished [55]. In addition, Picco et al. reported increased
intestinal permeability in all subtypes of JIA, further sug-
gesting aberrations in mucosal homeostasis in JIA, al-
though data on microbiome composition were lacking at
this stage [56]. New cross-sectional studies investigating
the composition of the microbiome in JIA patients in-
deed show that the gut microbiome is disturbed during
disease. A pilot study among DMARD-naïve polyarticu-
lar JIA patients revealed that intestinal microbiome di-
versity within the phylum Firmicutes is reduced [57].
Furthermore, a recent study conducted by Tejesvi et al.
analysed the composition of the faecal microbiota of
newly diagnosed, immunosuppressant-naive oligo- and
polyarticular JIA patients [11]. At the phylum level, they
found a higher abundance of Bacteroidetes in JIA patients,
whereas the abundance of Firmicutes was reduced. Like-
wise, at the genus level, a higher abundance of Bacteroides
was found in children with JIA compared to controls [11].
Both of these findings are in accordance with what has
previously been described in type 1 diabetes [6].
These cross-sectional studies intriguingly demon-
strate that microbial communities are disrupted dur-
ing disease. It can be assumed, however, that the
disease itself also induces changes in microbial com-
position due to associated long-term (systemic) in-
flammation, catabolism, or altered behaviour induced
by the symptoms of JIA. The question thus remains as
to whether the observed microbial dysbiosis is cause
or effect of the disease, or even a bystander effect,
since these studies still lack an associative character
with disease pathogenesis.
Recently, two case-control studies exploring the asso-
ciation between antibiotic exposure and the consecutive
development of JIA, did attempt to unravel cause and ef-
fect relationships [12, 13]. These data are particularly in-
teresting since it involves the use of antibiotics in
childhood, in which the microbiota is still developing and
therefore more vulnerable to disruption [58]. Arvonen et
al. confirmed the association between exposure to antibi-
otics and risk of JIA, and additionally, demonstrated that
the risk increased with repeated exposure [12]. They
observed the strongest associations with treatment
with lincosamides (e.g. clindamycin) and cephalospo-
rins, which especially target gram-positive microor-
ganisms leaving gram-negative (LPS-producing) bacteria
unharmed. Horton et al. reported a similar association
between antibiotic exposure and JIA development in a
retrospective case control study analysing data from >500
general practitioners in the UK. They confirm an in-
crease in risk with cumulative antibiotic exposure
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[13]. In addition, they observed the strongest association
with antibiotics prescribed within 1 year preceding the
diagnosis: interestingly in contrast to antibacterial drugs,
non-bacterial antimicrobial agents (i.e. antiviral or antifun-
gal) were not associated with the development of JIA [13].
A growing body of evidence suggests that even short-term
exposure to antimicrobial agents may have lasting effects
on the quantity and composition of the intestinal micro-
biota in general [10].
The major limitation of these case-control studies is
the risk of confounding: the association between anti-
biotic use and the development of JIA may also reflect,
for example, treatment of the first symptoms of JIA with
antibiotics, or alternatively be attributed to increased
susceptibility to infections in JIA [12]. Infections them-
selves may even explain both the increased use of antibi-
otics, microbiota dysregulation and JIA susceptibility. In
addition, conflicting data arise from these case-control
studies, cross-sectional studies (e.g. Tejesvi et al.), and
fundamental research. For example, clindamycin – one
of the antibiotics which use has been associated with
JIA, as described above [12] – specifically targets anaer-
obic bacteria, and has indeed been shown to have a
negative impact on the intestinal microbiota [59, 60].
However, Bacteroides, an important group of these an-
aerobic bacteria dominating the gut microbiota, has
been implicated to be essential for the maintenance of
functional stability of the human gut [10]. In addition
Bacteroides, specifically B. fragilis, is regarded to be
critical for adequate Treg development [61]. Contrast-
ingly, Tejesvi et al. describe an increase in the phylum
Bacteroidetes as opposed to a decrease what would be
expected if clindamycin played a major role [11]. One
explanation for the contradictory evidence may be
that it is not the increase or decrease in Bacteroidetes
that matters most, but rather the ratio between Bac-
teroidetes and Firmicutes or changes in specific spe-
cies within a population, e.g. Clostridia of the phylum
Firmicutes, which was also found to be reduced [11, 57].
Following clindamycin treatment, an increase in Bacteroi-
detes could also be explained by the generation of
clindamycin-resistant species, which has previously been
described [60, 62].
From the observations made so far, one may at least
conclude that there is evidence for microbial dysbiosis in
JIA patients. However, the question as to what triggers
this shift, what bacteria are actually beneficial or harm-
ful, and whether the associations are part of cause and
effect relationships, remains unanswered. Longitudinal
studies, preferably cohort studies, should be performed
in order to investigate whether the microbiome has a
causal relationship to the development of JIA.
Another interesting thought is whether diet can ex-
plain part of the link between microbiota dysregulation
and JIA, especially considering the differences in JIA epi-
demiology throughout the world. It is known that the
overall prevalence of JIA is much lower in Asia than in
Europe and North America [2]. Also the prevalence of
Table 1 Evidence for the involvement of the microbiome in JIA
Author & year Patients & healthy controls (n) Medication use Study conclusion
Aberrations in mucosal homeostasis
Malin 1996 [54] Oligo-JIA (19)
Poly-JIA (6)
ERA (1)
HC (26)
Mixed ↑ Bacterial urease activity in faeces of JIA patients
Picco 2000 [56] Oligo-JIA (26)
Mixed other (14)
Unknown ↑ Intestinal permeability in all subtypes of JIA
Microbiota composition
Hissink-Müller 2013 [57] Poly-JIA (8)
HC (24)
DMARD naive ↓ Firmicutes in JIA patients
Tejesvi 2016 [11] Oligo-JIA (13)
Poly-JIA (16)
ERA (1)
HC (27)
DMARD naive ↓ Bacteroidetes;↓ Firmicutes in JIA Genera Actinobacteria
and Fusobacteria only present in JIA
Childhood antibiotic use
Horton 2015 [13] JIA (152)
HC (1520)
Unknown Association between antibiotic exposure and JIA
(dose and time-dependent);
No association with nonbacterial antimicrobial agents
Arvonen 2015 [12] JIA (1298)
HC (5179)
Unknown Association between antibiotic exposure and JIA
(dose-dependent);
strongest for lincosamides and cephalosporins
Abbreviations: HC healthy control, ERA enthesitis-related arthritis; ↑ = increased, ↓ = decreased
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JIA subtypes varies widely, where oligoarticular JIA is
the most common subtype among Caucasians but much
less frequently occurs in, for example India [63]. It is
known that diet influences the composition of the
microbiota across geographic areas [64]. One must,
however, also take into account that genetics and envir-
onment also strongly differ throughout the world, which
renders it difficult to draw definite conclusions on the
role of diet alone.
Future challenges and perspectives
Taking into consideration both previous thoughts and
new insights, we propose an updated model for the
pathogenesis of JIA that integrates microbial dysbiosis
(Fig. 1). However, much work still needs to be done in
order to verify the associations that are made and un-
ravel the mechanistic underpinnings.
A number of important questions remain outstanding.
For instance, it is likely that next to environmental fac-
tors, host genetics may also impact the composition of
our microbiome, and thereby play a crucial early role in
defining disease susceptibility. In contrast, one might
also reason that dysbiosis is primarily the result of exter-
nal environmental factors, and that genetic factors only
come to play a role when dysbiosis is already present.
Another interesting question is whether disease results
from small or rather broad alterations in microbial com-
munities, and whether either the absence or the pres-
ence of specific bacteria are key. Furthermore, next to
the gut microbiome, there are now indications that also
the microbiome from other body sites, such as the oral
cavity and respiratory tract, may play a role, which was
recently reviewed extensively for RA [65] – although
these might likely be co-associated with alterations in
gut microbiota, since all these niches are communicating
and therefore can be all considered part of the human
microbiome.
A deeper understanding of the pathways by which dis-
turbances in the microbiome may evolve to disease may
open doors to the development of new treatment or pre-
vention strategies in the future. One approach to restore
the normal healthy gut microbiome is to replace it by
means of Faecal Microbiota Transplantation (FMT),
which proved to be very effective in the treatment of
refractory Clostridium difficile infections as well as in
ulcerative colitis [66, 67]. Alternatively, an attempt
could be made to restore the microbial community by
introducing anti-inflammatory commensals through
pro-/prebiotics or dietary interventions. Interestingly,
initiatives are now being taken to culture targeted com-
binations of bacteria in vitro that can restore intestinal
homeostasis [68, 69].
Conclusions
A growing body of evidence indicates involvement of the
gut microbiome in the pathogenesis of JIA. Nevertheless,
much work still needs to be done to understand how the
interplay between genetics, the microbiome and other
possible environmental factors eventually results in
the development of chronic immune-mediated arth-
ritis, such as JIA. A better understanding of the inter-
actions between the host and microbiome may help
to establish alternative ways in which to treat, or even
prevent disease.
Fig. 1 The potential role of the microbiome in the pathogenesis of JIA. Microbial dysbiosis may result in dysregulation of the immune system
through influencing the interaction with T cell subsets and the integrity of the mucosal barrier. Altered mucosal permeability may in turn also
influence the direction in which T cell subsets develop. Together with genetic susceptibility and environmental triggers, this may result in
autoimmunity and joint inflammation
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